Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Recovery of ovarian function by human embryonic stem cell-derived mesenchymal stem cells in cisplatin-induced premature ovarian failure in mice

Fig. 3

Improved survival rate and changes in body weight of mice treated with cisplatin by hESC-MSC transplantation and tracking of hESC-MSC distribution in vivo. Total numbers of mice were 72, 97, and 75 in the control (CON), PBS, and hESC-MSC treatment groups, respectively. b, c Body weights were measured each day during cisplatin administration and again 2 and 4 weeks after hESC-MSCs transplantation. *P < 0.05, **P < 0.001. d Tracking of hESC-MSC distribution in vivo by Molday ION B with Prussian blue staining. e Nested PCR detection of human Sry gene. The control gene was mouse GAPDH (mgapdh). MM, molecular marker; L, liver; M, muscle; O, ovary; U, uterus; S, spleen

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512